Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Isabel Leite

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Frontiers in Neurology|July 17, 2020
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence WorldwideJyh Yung Hor, Nasrin Asgari, Ichiro Nakashima, et al.
Acta Neuropathologica Communications|December 7, 2017
Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody diseaseMaciej Jurynczyk, Fay Probert, Tianrong Yeo, et al.
Brain : a Journal of Neurology|May 23, 2018
Distinct HLA associations of LGI1 and CASPR2-antibody diseasesSophie Binks, James Varley, Wanseon Lee, et al.
The Lancet. Neurology|April 20, 2026
Identification of genetic risk loci associated with aquaporin 4-positive neuromyelitis optica spectrum disorder: a genome-wide association studyKathrine E Attfield, Angelos P Armen, Subita Balaram Kuttikkatte, et al.
Nature Reviews. Neurology|September 3, 2024
The influence of MOGAD on diagnosis of multiple sclerosis using MRIRuth Geraldes, Georgina Arrambide, Brenda Banwell, et al.
JAMA Neurology|January 7, 2018
Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseYael Hacohen, Yu Yi Wong, Christian Lechner, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyJames F Howard, Saskia Bresch, Angela Genge, et al.
Therapeutic Advances in Neurological Disorders|April 19, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension studyJames F Howard, Saskia Bresch, Constantine Farmakidis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 31, 2023
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and SatralizumabFriedemann Paul, Romain Marignier, Jacqueline Palace, et al.
The Lancet. Psychiatry|December 12, 2025
The distinctive psychopathology of NMDAR-antibody encephalitis compared with primary psychoses: an international, multicentre, retrospective phenotypic analysisAdam Al-Diwani, Jakob Theorell, Tarek Zghoul, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Frontiers in Neurology|July 17, 2020
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence WorldwideJyh Yung Hor, Nasrin Asgari, Ichiro Nakashima, et al.
Acta Neuropathologica Communications|December 7, 2017
Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody diseaseMaciej Jurynczyk, Fay Probert, Tianrong Yeo, et al.
Brain : a Journal of Neurology|May 23, 2018
Distinct HLA associations of LGI1 and CASPR2-antibody diseasesSophie Binks, James Varley, Wanseon Lee, et al.
The Lancet. Neurology|April 20, 2026
Identification of genetic risk loci associated with aquaporin 4-positive neuromyelitis optica spectrum disorder: a genome-wide association studyKathrine E Attfield, Angelos P Armen, Subita Balaram Kuttikkatte, et al.
Nature Reviews. Neurology|September 3, 2024
The influence of MOGAD on diagnosis of multiple sclerosis using MRIRuth Geraldes, Georgina Arrambide, Brenda Banwell, et al.
JAMA Neurology|January 7, 2018
Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseYael Hacohen, Yu Yi Wong, Christian Lechner, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyJames F Howard, Saskia Bresch, Angela Genge, et al.
Therapeutic Advances in Neurological Disorders|April 19, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension studyJames F Howard, Saskia Bresch, Constantine Farmakidis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 31, 2023
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and SatralizumabFriedemann Paul, Romain Marignier, Jacqueline Palace, et al.
The Lancet. Psychiatry|December 12, 2025
The distinctive psychopathology of NMDAR-antibody encephalitis compared with primary psychoses: an international, multicentre, retrospective phenotypic analysisAdam Al-Diwani, Jakob Theorell, Tarek Zghoul, et al.
Pageof 8